Results 51 to 60 of about 37,376 (216)

Resistance to Fas-Mediated Apoptosis of Human T-Cell Lines Expressing Human T-Lymphotropic Virus Type-2 (HTLV-2) Tax Protein

open access: yesVirology, 2001
The susceptibility to Fas-mediated apoptosis was evaluated in seven T-cell lines (two infected with HTLV-2, one with HTLV-1, and four HTLV-free) as well as in Jurkat cells transfected with a Tax-2 expressing vector. Fas-mediated apoptosis was significantly reduced in the HTLV-1- and HTLV-2-infected lines in comparison with the HTLV-free lines ...
G. Zehender   +7 more
openaire   +4 more sources

Increased mortality associated with HTLV-II infection in blood donors: a prospective cohort study

open access: yesRetrovirology, 2004
Background HTLV-I is associated with adult T-cell leukemia, and both HTLV-I and -II are associated with HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Smith James W   +8 more
doaj   +1 more source

HIV-1 and HTLV-1 Transmission Modes: Mechanisms and Importance for Virus Spread

open access: yesViruses, 2022
So far, only two retroviruses, human immunodeficiency virus (HIV) (type 1 and 2) and human T-cell lymphotropic virus type 1 (HTLV-1), have been recognized as pathogenic for humans. Both viruses mainly infect CD4+ T lymphocytes.
Svetlana Kalinichenko   +2 more
doaj   +1 more source

Posttransplant lymphoproliferative disorders in neuronal xenotransplanted macaques [PDF]

open access: yes, 2016
Posttransplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of lymphoid proliferations that occur in the setting of depressed T-cell function due to immunosuppressive therapy used following solid organ transplantation, hematopoietic ...
Aron Badin, R.   +12 more
core   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

The prevalence of human T‐lymphotropic virus type 1 & 2 (HTLV‐1/2) in South African blood donors

open access: yesVox Sanguinis, 2019
Background and objectivesDonated blood is not currently screened for human T‐cell lymphotropic virus (HTLV) in South Africa. Several small studies have detected HTLV‐1 in South Africa, but prevalence by geographic region or population group is unavailable.Materials and MethodsWe performed a large seroprevalence study of South African blood donors ...
Marion Vermeulen   +13 more
openaire   +5 more sources

Pathways of cell-cell transmission of HTLV-1

open access: yesFrontiers in Microbiology, 2012
The deltaretroviruses human T-cell lymphotropic virus type 1 (HTLV-1) and human T-cell lymphotropic virus type 2 (HTLV-2) have long been believed to differ from retroviruses in other genera by their mode of transmission.
Claudine ePique   +2 more
doaj   +1 more source

Chronic adult T-cell Leukemia in a young male after blood transfusion as a newborn [PDF]

open access: yes, 2016
Human T-cell Lymphotropic virus type 1 (HTLV-1) is the etiological agent of Adult T-cell Leukemia/Lymphoma (ATLL) and HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HTM/TSP).
Altube, Alejandra   +10 more
core   +2 more sources

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli   +17 more
wiley   +1 more source

Silencers of HTLV-1 and HTLV-2: the pX-encoded latency-maintenance factors

open access: yesRetrovirology, 2019
Of the members of the primate T cell lymphotropic virus (PTLV) family, only the human T-cell leukemia virus type-1 (HTLV-1) causes disease in humans—as the etiological agent of adult T-cell leukemia/lymphoma (ATLL), HTLV-1-associated myelopathy/tropical ...
Robert Harrod
doaj   +1 more source

Home - About - Disclaimer - Privacy